Proteasome Inhibitors

Proteasome Inhibitor

Multiple Myeloma

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-10"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Ixazomib is a proteasome inhibitor. Ixazomib citrate, a prodrug, rapidly hydrolyzes under physiological conditions to its biologically active form, ixazomib. The chemical name of ixazomib citrate is 1,3,2-dioxaborolane-4,4-diacetic acid, 2-[(1<span class="Italics">R</span>)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-5-oxo- and the structural formula is:</p><div class="Figure"><img alt="Chemical Structure" src="ninlaro-01.jpg"/></div><p>The molecular formula for ixazomib citrate is C<span class="Sub">20</span>H<span class="Sub">23</span>BCl<span class="Sub">2</span>N<span class="Sub">2</span>O<span class="Sub">9 </span>and its molecular weight is 517.12. Ixazomib citrate has one chiral center and is the R-stereoisomer. The solubility of ixazomib citrate in 0.1N HCl (pH 1.2) at 37°C is 0.61 mg/mL (reported as ixazomib). The solubility increases as the pH increases.</p><p>NINLARO (ixazomib) capsules for oral use contain 4, 3 or 2.3 mg of ixazomib equivalent to 5.7, 4.3 or 3.3 mg of ixazomib citrate, respectively. Inactive ingredients include microcrystalline cellulose, magnesium stearate, and talc. Capsule shells contain gelatin and titanium dioxide. The 4 mg capsule shell contains red and yellow iron oxide, the 3 mg capsule shell contains black iron oxide and the 2.3 mg capsule shell contains red iron oxide. The printing ink contains shellac, propylene glycol, potassium hydroxide, and black iron oxide.</p></section>

NINLARO

ixazomib

ixazomib 2.3 MG Oral Capsule

Ninlaro

ixazomib 2.3 MG Oral Capsule [Ninlaro]

ixazomib 3 MG Oral Capsule

ixazomib 3 MG Oral Capsule [Ninlaro]

ixazomib 4 MG Oral Capsule

ixazomib 4 MG Oral Capsule [Ninlaro]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information

Medication Guide 

Submit MSL Request 

Pharmacy List 

Coverage Authorization Request 

Coverage Authorization Appeals 

Letter of Medical Necessity 

Takeda Oncology Here2Assist Enrollment Form 

Takeda Oncology Here2Assist Enrollment Form - Spanish 

Enroll in Patient Savings Program 

Takeda Oncology Patient Assistance Program

Takeda Oncology Patient Assistance Program - Spanish

Other HCP Resources 

Treatment Calendar 

Takeda Oncology Here2Assist Brochure 

Patient Experience Guide

Multiple Myeloma Treatment Trends

Patient Profiles 

About Ninlaro

Taking Ninlaro

FAQs: Multiple Myeloma 

Patient Resources 

Patient Experience Guide - Spanish 

Lab Test Tracker

Ninlaro Community 

Other Patient Resources 

Doctor Discussion Guide 

Instructions For Use: Mutilple Myeloma 